Griffith, Sarah P. http://orcid.org/0000-0002-7087-8703
Wesselingh, Robb
Seery, Nabil
Rushen, Tiffany
Kyndt, Chris
Long, Brian
Seneviratne, Udaya
Kalincik, Tomas
Buzzard, Katherine
Butzkueven, Helmut
O’Brien, Terence J.
Alpitsis, Rubina
Malpas, Charles B.
Monif, Mastura http://orcid.org/0000-0001-6404-9768
,
Funding for this research was provided by:
National Health and Medical Research Council (APP1201062)
Monash University
Article History
Received: 19 March 2024
Revised: 10 June 2024
Accepted: 15 June 2024
First Online: 25 June 2024
Declarations
:
: Prof Terence O’Brien has received support from the National Health and Medical Research Council, The National Institute of Neurological Disorders and Stroke and Monash University. He has been supported by research grants and consultancies to his institution from Eisai, UCB Pharma, Praxis Precision Medicines, BioGen and Supernus. A/Prof Mastura Monif has received research support from National Health and Medical Research Council, Medical Research Future Fund, Brain Foundation, Charles and Sylvia Viertel Foundation, and MS Research Australia. MM has also been supported by research grants. She has served on on advisory board for Merck, has received speaker honoraria from Merk and Biogen and Roche. Dr Katherine Buzzard has received speaker’s honoraria and/or conference support from Biogen, Alexion, Merck, Sanofi Genzyme, Teva, Novartis and Roche. KB has received research grants from CSL and has served on advisory boards for Merck and Biogen. Prof Helmut Butzkueven’s research is funded by an Australian National Health Medical Research Council Investigator Grant. His institution receives funding from Biogen, Roche, Merck, Alexion and Novartis for speaker engagements, study steering and advisory committee service. He is on the editorial board of Multiple Sclerosis and Related Disorders and the Steering committee of the Brain Health Initiative (Oxford Health Policy Forum). Associate Professor Charles Malpas has received conference travel support from Merck, Novartis, and Biogen. He has received research support from the National Health and Medical Research Council, Multiple Sclerosis Research Australia, The University of Melbourne, The Royal Melbourne Hospital Neuroscience Foundation, and Dementia Australia. Associate Professor Udaya Seneviratne has received travel and speaker honoraria from Eisai Australia and LivaNova Australia. Professor Tomas Kalincik served on scientific advisory boards for Roche, Sanofi Genzyme, Novartis, Merck KGaA and Biogen, steering committee for Brain Atrophy Initiative by Sanofi Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Sanofi-Genzyme, Teva, BioCSL and Merck KGaA and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene and Merck KGaA. The remaining authors report no conflicts of interest.